Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.59 |
| ▸ | GAA | P10253 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23652487 | 0.95 | GAA (0.58) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL12946054 | 0.88 | MAPK13 (0.47) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL1519245 | 0.85 | MAPT (0.59) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL9950077 | 0.84 | GAA (0.52) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL11468680 | 0.81 | KDM4E (0.56) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL29548950 | 0.81 | MAPK14 (0.43) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL3013794 | 0.81 | MAPK14 (0.43) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL11400584 | 0.81 | MAPK13 (0.49) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL16239045 | 0.81 | KEAP1 (0.55) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL23652372 | 0.80 | MAPT (0.58) | MAPTGAAKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111224002-B | Organometallic compound and organic light emitting device including the same | 三星显示有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-20230120308-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
| EP-4124619-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | Idemitsu Kosan Co., Ltd. (JP) | 2023-02-01 | — | — | EP | disclosed |
| CN-111224002-A | Organometallic compound and organic light emitting device including the same | 三星显示有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20200168816-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-05-28 | — | — | US | disclosed |
| WO-2019078636-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | 희성소재(주) | 2019-04-25 | — | — | WO | disclosed |
| EP-3053985-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME | LG CHEMICAL LTD (KR) | 2018-10-31 | — | — | EP | disclosed |
| US-10032997-B2 | Heterocyclic compound and organic light-emitting element using same | LG CHEM, LTD. (KR) | 2018-07-24 | — | — | US | disclosed |
| US-20180123053-A1 | BIPOLAR MATERIALS AND ORGANIC LIGHT EMITTING DIODES | YUAN ZE UNIVERSITY (TW) | 2018-05-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120308-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | ODC1, OR10J3, PIEZO1 | MAPT 1600/4885GAA 1046/4885KDM4E 1561/4885 |
| US-10032997-B2 | Heterocyclic compound and organic light-emitting element using same | CRY1, CRY2, NR2E3 | MAPT 1252/4885GAA 1696/4885KDM4E 1127/4885 |
| US-20180123053-A1 | BIPOLAR MATERIALS AND ORGANIC LIGHT EMITTING DIODES | MAP1LC3A, MAP1LC3B, MAP1LC3C | MAPT 106/4885GAA 3109/4885KDM4E 3086/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | MAPT 1654/4885GAA 1689/4885KDM4E 3387/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | MAPT 3825/4885GAA 2198/4885KDM4E 1473/4885 |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CYP1B1, CRY2 | MAPT 2733/4885GAA 3322/4885KDM4E 3112/4885 |
| US-20200168816-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CHRM1, L1CAM, L3MBTL1 | MAPT 1510/4885GAA 3950/4885KDM4E 1577/4885 |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | EHD1, HCN2, ODC1 | MAPT 3456/4885GAA 4277/4885KDM4E 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.